US Pharma MarketingEtcamah is the second oral “SERD” to recently fall short in first-line breast cancer, following a similar setback from Roche earlier this year.
AstraZeneca’s newly approved pill fails frontline breast cancer study
Etcamah is the second oral “SERD” to recently fall short in first-line breast cancer, following a similar setback from Roche earlier this year.
Source: BioPharma Dive